Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Graff

Showing results (241-250 of 245) with videos related to

Pageof 25
Sort By:
You have reached the last page of results.This site can display upto 245 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 10, 2023
Lasofoxifene versus fulvestrant for ER+/HER2- metastatic breast cancer with an ESR1 mutation: results from the randomized, phase II ELAINE 1 trialM P Goetz, N A Bagegni, G Batist, et al.
Cancer Drug Resistance (Alhambra, Calif.)|June 13, 2025
Acquired resistance to molecularly targeted therapies for cancerNolan M Stubbs, Tyler J Roady, Maximilian P Schwermann, et al.
ESMO Open|August 14, 2025
Safety of having a subsequent pregnancy after prior diagnosis of breast cancer during pregnancy in young BRCA carriersM Perachino, E Blondeaux, V Delucchi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 22, 2024
Impact of hormone receptor status and tumor subtypes of breast cancer in young BRCA carriersL Arecco, M Bruzzone, R Bas, et al.
Oncotarget|March 12, 2025
Worldwide Innovative Network (WIN) Consortium in Personalized Cancer Medicine: Bringing next-generation precision oncology to patientsWafik S El-Deiry, Catherine Bresson, Fanny Wunder, et al.
Pageof 25

Showing results (241-250 of 245) with videos related to

Sort By:
Pageof 25
You have reached the last page of results.This site can display upto 245 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 10, 2023
Lasofoxifene versus fulvestrant for ER+/HER2- metastatic breast cancer with an ESR1 mutation: results from the randomized, phase II ELAINE 1 trialM P Goetz, N A Bagegni, G Batist, et al.
Cancer Drug Resistance (Alhambra, Calif.)|June 13, 2025
Acquired resistance to molecularly targeted therapies for cancerNolan M Stubbs, Tyler J Roady, Maximilian P Schwermann, et al.
ESMO Open|August 14, 2025
Safety of having a subsequent pregnancy after prior diagnosis of breast cancer during pregnancy in young BRCA carriersM Perachino, E Blondeaux, V Delucchi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 22, 2024
Impact of hormone receptor status and tumor subtypes of breast cancer in young BRCA carriersL Arecco, M Bruzzone, R Bas, et al.
Oncotarget|March 12, 2025
Worldwide Innovative Network (WIN) Consortium in Personalized Cancer Medicine: Bringing next-generation precision oncology to patientsWafik S El-Deiry, Catherine Bresson, Fanny Wunder, et al.
Pageof 25